Skip Navigation


Brain Advance Access originally published online on August 22, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
126/11/2558    most recent
awg260v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mills, K. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mills, K. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 126, No. 11, 2558-2566, November 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg260

The natural history of central motor abnormalities in amyotrophic lateral sclerosis

K. R. Mills

Academic Unit of Clinical Neurophysiology, Guy’s, King’s and St Thomas’ School of Medicine, King’s College Hospital, London, UK

Correspondence to: Kerry Mills, Academic Unit of Clinical Neurophysiology, Guy’s, King’s and St Thomas’ School of Medicine, King’s College Hospital, Denmark Hill, London SE5 9RS, UK E-mail: K.Mills{at}iop.kcl.ac.uk

Degeneration of spinal motoneurons has been well documented in amyotrophic lateral sclerosis (ALS), but the evolution of central motor abnormalities is largely unknown. It has been suggested that glutamate- mediated neuroexcitotoxicity may be involved in the pathogenesis of ALS and that this may be manifest as an increase in corticomotor excitability early in the disease. Serial measurements of corticomotor threshold, central motor conduction time (CMCT), silent period duration and the amplitude of compound muscle action potentials (CMAPs) from ulnar nerve stimulation in the right and left first dorsal interosseous muscles were made in 76 patients with idiopathic ALS, 49 of whom were followed from presentation to death. Threshold to transcranial magnetic stimulation was determined by standard methods and CMCT was measured using the F-wave method. Silent period was estimated during a small background contraction of the muscle. Patients were classified according to the region of onset and the physical signs in the hands. The region of onset was bulbar in 17 patients, lower limb in 31 patients and upper limb in 28 patients. At presentation, 23 patients had no abnormal physical signs in the hands, 25 had lower motoneuron signs only, 14 had upper motoneuron signs only and the remainder (14) had mixed upper and lower motoneuron signs in the hands. Evolution of the central conduction parameters was determined in relation to time from onset of symptoms and also as a function of normalized total disease duration in the patients who had died. Corticomotor threshold and CMCT showed no change as the disease evolved except for patients with mixed signs, who had a terminal increase in threshold and prolongation of CMCT. Silent period duration was shorter than normal early in the disease and showed progressive lengthening throughout the illness, but nevertheless remained within the normal range regardless of the region of onset. CMAP amplitude showed a linear decline over the course of the disease. There was therefore no evidence of a phase of increased corticomotor hyperexcitability at any stage of disease progression. The early shortening of silent period, however, probably represents a shift in the balance of excitatory and inhibitory inputs to the cortical output cells responsible for voluntary action, and could be a reflection of degeneration of cortical interneurons. None of the measures of central motor function in ALS are likely to be useful for monitoring patients in a clinical trial setting.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
H. Mitsumoto, A. M. Ulug, S. L. Pullman, C. L. Gooch, S. Chan, M. -X. Tang, X. Mao, A. P. Hays, A. G. Floyd, V. Battista, et al.
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS
Neurology, April 24, 2007; 68(17): 1402 - 1410.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
S. Vucic and M. C. Kiernan
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease
Brain, September 1, 2006; 129(9): 2436 - 2446.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M R Turner, A D Osei-Lah, A Hammers, A Al-Chalabi, C E Shaw, P M Andersen, D J Brooks, P N Leigh, and K R Mills
Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS
J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1279 - 1285.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
R Nardone, E Buffone, I Florio, and F Tezzon
Changes in motor cortex excitability during muscle fatigue in amyotrophic lateral sclerosis
J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 429 - 431.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.